Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore

Novartis India Ltd has announced a major deal to acquire the trademarks for several key blood pressure medications from Pfizer Inc. The transaction, valued at approximately ₹1,250 crore, will transfer these established brands to Novartis, allowing the company to expand its portfolio in the cardiovascular segment. This move comes shortly after private-equity firm ChrysCapital acquired a controlling 70.68 per cent stake in Novartis India, signaling a strategic shift in the company's ownership and future direction.

For investors, this deal is significant as it strengthens Novartis India's position in a critical therapeutic area while potentially unlocking new growth avenues. The transfer of well-known brands is expected to bolster the company's revenue streams and market share. Following the acquisition by ChrysCapital, the market will closely watch how the new ownership integrates these assets and executes its growth strategy to maximize shareholder value.